

RECEIVED

MAY 25 2001

TECH CENTER 1600/2900
DOCKET NO. C-1639/7021

FORM PTO-1449/A and B (Modified)

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Sheet

2

MAY 21 2001
U.S. PATENT & TRADEMARK OFFICE

APPLICATION NO.: 09/337,619

ATTY. DOCKET NO. C-1639/7021

FILING DATE: June 21, 1999

APPLICANT: Krieg et al.

GROUP ART UNIT: 1633

EXAMINER: J. Martinell

U.S. PATENT DOCUMENTS

Examiner's Initials#	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY		
		Number	Kind Code		Class	Subclass	
<i>d</i>		5,679,647	B1	Carson et al.	54	44	10/21/1997
<i>d</i>		5,780,448	B1	Davis	54	44	07/14/1998
<i>d</i>		5,837,243	B1	Deo et al.	424	136.1	11/17/1998

FOREIGN PATENT DOCUMENTS


Examiner's Initials#	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
<i>d</i>		WO	96/02560	A1	University of NC at Chapel Hill	02/01/1996	
<i>d</i>		WO	98/32462	A1	Wagner et al.	07/30/1998	
<i>d</i>		WO	98/55495	A2	Dynavax Technologies Corp.	12/10/1998	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials#	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
<i>d</i>		AGGARWAL, S.K. et al., "Cell-Surface-Associated Nucleic Acid in Tumorigenic Cells Made Visible with Platinum-Complexes by Electron Microscopy", <i>Proc. Nat. Acad. Sci. USA</i> , March 1975, Pages 928-932, Vol. 72, No. 3	
<i>d</i>		KATAOKA, T. et al., "Antitumor Activity of Synthetic Oligonucleotides with Sequences from cDNA Encoding Proteins of <i>Mycobacterium bovis</i> BCG", <i>Jpn. J. Cancer Res.</i> , March 1992, Pages 244-247, Vol. 83	
<i>d</i>		KLINMAN, D.M. et al., "Contribution of CpG Motifs to the Immunogenicity of DNA Vaccines", <i>J. of Immunol.</i> , 1997, Pages 3635-3639, Vol. 158, No. 8, The American Association of Immunologists	
<i>d</i>		LIPFORD, G.B. et al., "CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants", <i>Eur. J. Immunol.</i> , 1997, Pages 2340-2344, Vol. 27	
<i>d</i>		LIPFORD, G.B. et al., "Bacterial DNA as immune cell activator", <i>Inst. of Med. Microb., Immunol. and Hygiene</i> , 1998, Pages 496-500, Elsevier Science	
<i>d</i>		STULL, R.A. et al., "Antigene, Ribozyme and Aptamer Nucleic Acid Drugs: Progress and Prospects", <i>Pharmaceutical Research</i> , 1995, Pages 465-483, Vol. 12, No. 4, Plenum Publishing Corp.	
<i>d</i>		SUN, S. et al., "Mitogenicity of DNA from Different Organisms for Murine B Cells", <i>The Journal of Immunology</i> , 1997, Pages 3119-3125, The American Association of Immunologists	
<i>d</i>		THREADGILL, D.S. et al., "Mitogenic synthetic polynucleotides suppress the antibody response to a bacterial polysaccharide", <i>Vaccine</i> , 1998, Pages 76-82, Vol. 16, No. 1, Elsevier Science Ltd.	
<i>d</i>		WILTROUT, R.H., et al., "Immunomodulation of Natural Killer Activity by Polyribonucleotides", <i>Journal of Biological Response Modifiers</i> , 1985, Pages 512-517, Vol. 4, No. 5, New Raven Press, NY	
<i>d</i>		WOOLDRIDGE, J.E. et al., "Select Unmethylated CpG Oligodeoxynucleotides Improve Antibody Dependent Cellular Cytotoxicity <i>in Vitro</i> of Both Murine and Human B Cell Lymphomas", <i>Blood</i> , December 1995, Page 2877, Abstract, Vol. 86	
<i>d</i>		WOOLDRIDGE, J.E. et al., "Select unmethylated CpG oligodeoxynucleotide improve antibody dependent cellular cytotoxicity <i>in vitro</i> and <i>in vivo</i> ", Proceedings of the American Association for Cancer Research #3253, March 1996, Page 477, Abstract, Vol. 37	

S. Bush

2/20/02



RECEIVED

MAY 25 2001

TECH CENTER 1600/2900

EXAMINER

DATE CONSIDERED

2/26/02

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).